BTIG analyst Thomas Shrader lowered the firm’s price target on Acumen (ABOS) to $4 from $11 and keeps a Buy rating on the shares. In a broader research note previewing Q3 results for select biotech names, the firm is updating its assumptions and models for the company, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABOS: